Polymer clay nanocomposites (NCs) show remarkable potential in the field of drug delivery due to their enhanced barrier properties. It is hypothesised that well dispersed clay particles within the polymer matrix create a tortuous pathway for diffusing therapeutic molecules, thereby resulting in more sustained release of the drug. As coatings for medical devices, these materials can simultaneously modulate drug release and improve the mechanical performance of an existing polymer system without introducing additional materials with new chemistries that can lead to regulatory concerns. In this study, polyurethane organosilicate nanocomposites (PUNCs) coated onto stainless steel wires were evaluated for their feasibility as blood compatible coatings and as drug delivery systems. Heparin was selected as the model drug to examine the impact of silicate loading and modifier chain length in modulating release. Findings revealed that better dispersion was achieved from samples with lower clay loadings and longer alkyl chains. The blood compatibility of PUNCs as assessed by thrombin generation assays showed that the addition of silicate particles did not significantly decrease the thrombin generation lag time (TGT, p = 0.659) or the peak thrombin ( p = 0.999) of polyurethane (PU). PUNC coatings fabricated in this research were not cytotoxic as examined by the cell growth inhibition assay and were uniformly intact, but had slightly higher growth inhibition compared to PU possibly due to the presence of organic modifiers (OM). The addition of heparin into PUNCs prolonged the TGT, indicating that heparin was still active after the coating process. Cumulative heparin release profiles showed that the majority of heparin released was from loosely attached residues on the surface of coils. The addition of heparin further prolonged the TGT as compared to coatings without added heparin, but a slight decrease in heparin activity was observed in the NCs. This was thought to be from competitive interactions between clay-heparin that influenced the formation of the ternary complex between heparin, ATIII thrombin. In summary, the feasibility of using PUNC as drug delivery coatings was shown by the good uniformity in the coating, absence of by-products from the coating process, and the release of active molecules without significantly interfering with their activity.
References
[1]
Hehrlein, C.; Arab, A.; Bode, C. Drug-eluting stent: The “magic bullet” for prevention of restenosis? Basic Res. Cardiol. 2002, 97, 417–423, doi:10.1007/s00395-002-0379-2.
[2]
Coronary Stenting: A Literature Review; Australian Health Technology Advisory Committee: Canberra, Australia, 1997.
[3]
Knetsch, M.L.W. Blood-contacting surfaces. In Biomaterials Fabrication and Processing; Chu, P.K., Liu, X., Eds.; CRC Press: Boca Raton, Florida, 2008.
[4]
Ikada, Y. Surface modification of polymers for medical applications. Biomaterials 1994, 15, 725–736, doi:10.1016/0142-9612(94)90025-6.
[5]
Han, D.K.; Park, K.D.; Ahn, K.D.; Jeong, S.Y.; Kim, Y.H. Preparation and surface characterization of PEO-grafted and heparin immobilized polyurethanes. J. Biomed. Mater. Res. 1989, 23, 87–104, doi:10.1002/jbm.820231309.
[6]
Du, Y.J.; Klement, P.; Berry, L.R.; Tressel, P.; Chan, A.K.C. In vivo rabbit acute model tests of polyurethane catheters coated with a novel antithrombin-heparin covalent complex. Thromb. Haemost. 2005, 94, 366–372, doi:10.1160/TH04-09-0581.
[7]
Zhou, Z.; Meyerhoff, M.E. Preparation and characterization of polymeric coatings with combined nitric oxide release and immobilized active heparin. Biomaterials 2005, 26, 6506–6517, doi:10.1016/j.biomaterials.2005.04.046.
[8]
Riedl, C.R.; Witkowski, M.; Plas, E.; Pflueger, H. Heparin coating reduces encrustation of ureteral stents: A preliminary report. Int. J. Antimicrobial Agents 2002, 19, 507–510.
[9]
Fu, J.; Ji, J.; Fan, D.; Shen, J. Construction of antibacterial multilayer films containing nanosilver via layer-by-layer assembly of heparin and chitosan-silver ions complex. J. Biomater. Res. 2006, 79, 665–674.
[10]
Tan, Q.; Ji, J.; Barbosa, M.A.; Fonseca, C.; Shen, J. Constructing thromboresistant surface on biomedical stainless steel via layer-by-layer deposition anticoagulant. Biomaterials 2003, 24, 4699–4705, doi:10.1016/S0142-9612(03)00363-6.
[11]
Tan, Q.; Ji, J.; Zhao, F.; Fan, D.Z.; Sun, F.Y.; Shen, J.C. Fabrication of thromboresistant multilayer thin film on plasma treated poly(vinyl chloride) surface. J. Mater. Sci-Mater. Med. 2005, 16, 687–692, doi:10.1007/s10856-005-2541-5.
[12]
Van der Heiden, A.P.; Goebbels, D.; Pijpers, A.P.; Koole, L.H. A photochemical method for the surface modification of poly(etherurethanes) with phosphorylcholine-containing compounds to improve hemocompatibility. J. Biomater. Res. 1997, 37, 282–290.
[13]
Desai, N.P.; Hubbell, J.A. Solution technique to incorporate polyethylene oxide and other water-soluble polymers into surfaces of polymeric biomaterials. Biomaterials 1991, 12, 144–153.
[14]
Mazid, M.A.; Scott, E.; Nai-Hong, L. New biocompatible polyurethane-type copolymer with low molecular weight heparin. Clin. Mater. 1991, 8, 71–80, doi:10.1016/0267-6605(91)90012-5.
[15]
Labarre, D.; Jozefowicz, M.; Boffa, M.C. Properties of heparin-poly (methyl methacrylate) copolymers. II. J. Biomed. Mater. Res. 1977, 11, 283–295.
[16]
Moon, H.T.; Lee, L.K.; Han, J.K.; Byun, Y. A novel formulation for controlled release of heparin-DOCA conjugate dispersed as nanoparticles in polyurethane film. Biomaterials 2001, 22, 281–289, doi:10.1016/S0142-9612(00)00194-0.
[17]
Huang, X.; Brazel, C.S. On the importance and mechanisms of burst release in matrix-controlled drug delivery systems. J. Control. Release 2001, 73, 121–136, doi:10.1016/S0168-3659(01)00248-6.
[18]
Deconinck, E.; Sohier, J.; Scheerder, I.D.; Van den Mooter, G. Pharmaceutical aspects of drug eluting stents. J. Pharm. Sci. 2008, 97, 5047–5060, doi:10.1002/jps.21356.
[19]
Chen, M.C.; Chang, Y.; Liu, C.T.; Lai, W.Y.; Peng, S.F.; Hung, Y.W.; Tsai, H.W.; Sung, H.W. The characteristics and in vivo suppression of neointimal formation with sirolimus-eluting polymeric stents. Biomaterials 2009, 30, 79–88, doi:10.1016/j.biomaterials.2008.09.006.
[20]
Lee, P.I. Effect of non-uniform initial drug concentration distribution on the kinetics of drug release from glassy hydrogel matrices. Polymer 1984, 25, 973–978, doi:10.1016/0032-3861(84)90082-X.
[21]
Endo, M.; Koyama, S.; Matsuda, Y.; Hayashi, T.; Kim, Y.A. Thrombogenicity and blood coagulation of a microcatheter prepared from carbon nanotubes-nylon based composite. Nano lett. 2004, 5, 101–105.
[22]
Kannan, R.Y.; Salacinski, H.J.; Groot, J.D.; Clatworthy, I.; Bozec, L.; Horton, M.; Butler, P.E.; Seifalian, A.M. The antithrombogenic potential of a polyhedral oligomeric silsesquioxane (POSS) nanocomposite. Biomacromolecules 2006, 7, 215–223, doi:10.1021/bm050590z.
Styan, K.E.; Martin, D.J.; Poole-Warren, L.A. In vitro fibroblast response to polyurethane organosilicate nanocomposites. J. Biomed. Mater. Res. Part A 2008, 86, 571–582.
[32]
Joshi, G.V.; Patel, H.; Bajaj, H.; Jasra, R. Intercalation and controlled release of vitamin B6 from montmorillonite-vitamin B6 hybrid. Colloid Polym. Sci. 2009, 287, 1071–1076, doi:10.1007/s00396-009-2067-3.
[33]
Suggs, L.J.; Shive, M.S.; Garcia, C.A.; Anderson, J.M.; Mikos, A.G. In vitro cytotoxicity and in vivo biocompatibility of poly(propylene fumarate-co-ethylene glycol) hydrogels. J. Biomed. Mater. Res. 1999, 46, 22–32, doi:10.1002/(SICI)1097-4636(199907)46:1<22::AID-JBM3>3.0.CO;2-R.
[34]
Rosengren, A.; Faxius, L.; Tanaka, N.; Watanabe, M.; Bjursten, L.M. Comparison of implantation and cytotoxicity testing for initially toxic biomaterials. J. Biomed. Mater. Res. Part A 2005, 75, 115–122.
[35]
Bounameaux, H. Unfractionated versus low-molecular-weight heparin in the treatment of benous thromboembolism. Vasc. Med. 1998, 3, 41.
Duncan, A.C.; Sefton, M.V.; Brash, J.L. Effect of C4-, C8- and C18- alkylation of poly(vinyl alcohol) hydrogels on the adsorption of albumin and fibrinogen from buffer and plasma: Limited correlation with platelet interactions. Biomaterials 1997, 18, 1585–1592, doi:10.1016/S0142-9612(97)00100-2.
Heuck, C.C.; Schiele, U.; Horn, D.; Fronda, D.; Ritz, E. The role of surface charge on the accelerating action of heparin on the antithrombin III-inhibited activity of α-Thrombin. J. Biol. Chem. 1985, 260, 4598–4603.
[40]
Biological Evaluation of Medical Devices; AS-ISO-10993, Standards Australia International Ltd, Sydney, Austrilia, 2004.
[41]
Jaques, L.B.; Monkhouse, F.C.; Stewart, M. A method for the determination of heparin in blood. J. Physiol. 1949, 109, 41–48.
[42]
Hemker, H.C.; Giesen, P.; AlDieri, R.; Regnault, T.; de Smed, E.; Wagenvoord, R. The calibrated automated thrombogram (CAT): A universal routine test for hyper- and hypocoagulability. Pathophysiol. Haemost. Thromb. 2002, 32, 249–253, doi:10.1159/000073575.
